A Randomized, double-blind, placebo-controlled, dose and active comparator-controlled dose-response study of rivoglitazone (CS-011) in patients with type 2 diabetes

Trial Profile

A Randomized, double-blind, placebo-controlled, dose and active comparator-controlled dose-response study of rivoglitazone (CS-011) in patients with type 2 diabetes

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2011

At a glance

  • Drugs Pioglitazone; Rivoglitazone
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms RAISE
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Sep 2011 Results published in the Diabetes, Obesity and Metabolism.
    • 05 Feb 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top